Macrophage proliferation and apoptosis in atherosclerosis

Current Opinion in Lipidology

Volumn 23, Issue 5, 2012, Pages 429-438

  Andrés, Vicente ^a   Pello, Oscar M ^a   Silvestre Roig, Carlos ^a  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

apoptosis; atherosclerosis; cell proliferation; macrophage

Indexed keywords

C REACTIVE PROTEIN; COLONY STIMULATING FACTOR 1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIPOPROTEIN; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN P53;

APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOCRINE EFFECT; CARDIOVASCULAR RISK; CELL CYCLE REGULATION; CELL PROLIFERATION; DISEASE COURSE; ENDOPLASMIC RETICULUM STRESS; HEART INFARCTION; HUMAN; INFLAMMATION; MACROPHAGE FUNCTION; MACROPHAGE MIGRATION; MONOCYTE; NONHUMAN; OXIDATION; PARACRINE SIGNALING; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOSIS; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; CELL PROLIFERATION; DISEASE PROGRESSION; ENDOPLASMIC RETICULUM STRESS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MICE; NECROSIS; PHAGOCYTOSIS; PLAQUE, ATHEROSCLEROTIC;

EID: 84866318436     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328357a379     Document Type: Review

References (93)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349:1498-1504. (Pubitemid 27216360)
3. Mackay J, Mensah GA. The atlas of heart disease and stroke. Geneva: WHO. http://www.who.int/cardiovascular-diseases/resources/atlas/en/2004.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-809. (Pubitemid 23132154)
5. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nature Med 2002; 8:1211-1217. (Pubitemid 35373551)
6. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011; 145:341-355.
7. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11:723-737.
8. Khallou-Laschet J, Varthaman A, Fornasa G, et al. Macrophage plasticity in experimental atherosclerosis. PLoS One 2010; 5:e8852.
9. Pello OM, Silvestre C, De Pizzol M, Andres V. A glimpse on the phenomenon of macrophage polarization during atherosclerosis. Immunobiology 2012; 216:1172-1176.
10. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27:451-483.
11. Gratchev A, Kzhyshkowska J, Utikal J, Goerdt S. Interleukin-4 and dexametha-sone counterregulate extracellular matrix remodelling and phagocytosis in type-2 macrophages. Scand J Immunol 2005; 61:10-17. (Pubitemid 40188343)
12. Xu W, Roos A, Schlagwein N, et al. IL-10-producing macrophages preferentially clear early apoptotic cells. Blood 2006; 107:4930-4937. (Pubitemid 43882647)
13. Jenkins SJ, Ruckerl D, Cook PC, et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 2011; 332:1284-1288.
14. Gordon D, Reidy MA, Benditt EP, Schwartz SM. Cell proliferation in human coronary arteries. Proc Natl Acad Sci USA 1990; 87:4600-4604. (Pubitemid 20204150)
15. Rekhter MD, Gordon D. Active proliferation of different cell types, including lymphocytes, in human atherosclerotic plaques. AmJ Pathol 1995; 147:668-677.
16. Kearney M, Pieczek A, Haley L, et al. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation 1997; 95:1998-2002. (Pubitemid 27184264)
17. Rosenfeld ME, Ross R. Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis 1990; 10:680-687. (Pubitemid 20273338)
18. Spagnoli LG, Orlandi A, Santeusanio G. Foam cells of the rabbit atherosclerotic plaque arrested in metaphase by colchicine show a macrophage phenotype. Atherosclerosis 1991; 88:87-92.
19. Diez-Juan A, Andres V. The growth suppressor p27(Kip1) protects against diet-induced atherosclerosis. FASEB J 2001; 15:1989-1995. (Pubitemid 32848803)
20. Diez-Juan A, Perez P, Aracil M, et al. Selective inactivation of p27(Kip1) in hematopoietic progenitor cells increases neointimal macrophage proliferation and accelerates atherosclerosis. Blood 2004; 103:158-161. (Pubitemid 38029933)
21. Mercer J, Figg N, Stoneman V, et al. Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice. Circ Res 2005; 96:667-674. (Pubitemid 40478334)
22. Fuster JJ, Fernandez P, Gonzalez-Navarro H, et al. Control of cell proliferation in atherosclerosis: insights from animal models and human studies. Cardio-vasc Res 2010; 86:254-264.
23. Boesten LS, Zadelaar AS, van Nieuwkoop A, et al. Macrophage retinoblas-toma deficiency leads to enhanced atherosclerosis development in ApoE-deficient mice. FASEB J 2006; 20:953-955.
24. Guevara NV, Kim HS, Antonova EI, Chan L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nature Med 1999; 5:335-339. (Pubitemid 29124372)
25. van Vlijmen BJ, Gerritsen G, Franken AL, et al. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ Res 2001; 88:780-786. (Pubitemid 32429973)
26. Merched AJ, Williams E, Chan L. Macrophage-specific p53 expression plays a crucial role in atherosclerosis development and plaque remodeling. Arterioscler Thromb Vasc Biol 2003; 23:1608-1614. (Pubitemid 37108205)
27. Boesten LS, Zadelaar AS, van Nieuwkoop A, et al. Macrophage p53 controls macrophage death in atherosclerotic lesions of apolipoprotein E deficient mice. Atherosclerosis 2009; 207:399-404.
28. Sanz-Gonzalez SM, Barquin L, Garcia-Cao I, et al. Increased p53 gene dosage reduces neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis. Cardiovasc Res 2007; 75:803-812. (Pubitemid 47238733)
29. Merched AJ, Chan L. Absence of p21Waf1/Cip1/Sdi1 modulates macrophage differentiation and inflammatory response and protects against atherosclerosis. Circulation 2004; 110:3830-3841. (Pubitemid 40023982)
30. Akyurek LM, Boehm M, Olive M, et al. Deficiency of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1 accelerates atherogenesis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 2010; 396:359-363.
31. González-Navarro H, Abu Nabah YN, Vinue A, et al. p19(ARF) deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. J Am Coll Cardiol 2010; 55:2258-2268.
32. Kuo CL, Murphy AJ, Sayers S, et al. Cdkn2a is an atherosclerosis modifier locus that regulates monocyte/macrophage proliferation. Arterioscler Thromb Vasc Biol 2011; 31:2483-2492.
33. Wouters K, Cudejko C, Gijbels MJ, et al. Bone marrow p16INK4a-deficiency does not modulate obesity, glucose homeostasis or atherosclerosis development. PLoS One 2012; 7:e32440.
34. Smith JD, Trogan E, Ginsberg M, et al. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995; 92:8264-8268.
35. Qiao JH, Tripathi J, Mishra NK, et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 1997; 150:1687-1699. (Pubitemid 27193816)
36. Shiba Y, Takahashi M, Yoshioka T, et al. M-CSF accelerates neointimal formation in the early phase after vascular injury in mice: the critical role of the SDF-1-CXCR4 system. Arterioscler Thromb Vasc Biol 2007; 27:283-289. (Pubitemid 46143041)
37. Zhu SN, Chen M, Jongstra-Bilen J, Cybulsky MI. GM-CSF regulates intimal cell proliferation in nascent atherosclerotic lesions. J Exp Med 2009; 206:2141-2149.
38. Shaposhnik Z, Wang X, Weinstein M, et al. Granulocyte macrophage colony-stimulating factor regulates dendritic cell content of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2007; 27:621-627.
39. Ditiatkovski M, Toh BH, Bobik A. GM-CSF deficiency reduces macrophage PPAR-gamma expression and aggravates atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26:2337-2344. (Pubitemid 44465731)
40. Haghighat A, Weiss D, Whalin MK, et al. Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor exacerbate atherosclerosis in apolipoprotein E-deficient mice. Circulation 2007; 115:2049-2054. (Pubitemid 46625956)
41. Lamharzi N, Renard CB, Kramer F, et al. Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: potential role of glucose-oxidized LDL Diabetes 2004; 53:3217-3225. (Pubitemid 39564498)
42. Holdt LM, Teupser D. Recent studies of the human chromosome 9p21 locus, which is associated with atherosclerosis in human populations. Arterioscler Thromb Vasc Biol 2012; 32:196-206.
43. Holdt LM, Sass K, Gabel G, et al. Expression of Chr9p21 genes CDKN2B (p15(INK4b)), CDKN2A (p16(INK4a), p14(ARF)) and MTAP in human ather osclerotic plaque. Atherosclerosis 2011; 214:264-270.
44. Cudejko C, Wouters K, Fuentes L, et al. p16INK4a deficiency promotes IL-4-induced polarization and inhibits proinflammatory signaling in macrophages. Blood 2011; 118:2556-2566.
45. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8:533-544. (Pubitemid 351913679)
46. Donnelly LH, Bree MP, Hunter SE, et al. Immunoreactive macrophage colony-stimulating factor is increased in atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits after recombinant human macrophage colony-stimulating factor therapy. Mol Reprod Dev 1997; 46:92-95. (Pubitemid 27021359)
47. Finkelstein A, Makkar R, Doherty TM, et al. Increased expression of macro-phage colony-stimulating factor after coronary artery balloon injury is inhibited by intracoronary brachytherapy. Circulation 2002; 105:2411-2415. (Pubitemid 34556394)
48. Saitoh T, Kishida H, Tsukada Y, et al. Clinical significance of increased plasma concentration of macrophage colony-stimulating factor in patients with angina pectoris. J Am Coll Cardiol 2000; 35:655-665. (Pubitemid 30167022)
49. Devaraj S, Yun JM, Duncan-Staley C, Jialal I. C-reactive protein induces M-CSF release and macrophage proliferation. J Leukoc Biol 2009; 85:262-267.
50. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003; 41:37S-42S. (Pubitemid 36223345)
51. Inoue I, Inaba T, Motoyoshi K, et al. Macrophage colony stimulating factor prevents the progression of atherosclerosis in Watanabe heritable hyperlipi-demic rabbits. Atherosclerosis 1992; 93:245-254.
52. Watanabe Y, Inaba T, Gotoda T, et al. Role of macrophage colony-stimulating factor in the initial process of atherosclerosis. Ann N Y Acad Sci 1995; 748:357-364; discussion 364-356.
53. Shindo J, Ishibashi T, Yokoyama K, et al. Granulocyte-macrophage colony-stimulating factor prevents the progression of atherosclerosis via changes in the cellular and extracellular composition of atherosclerotic lesions in wata-nabe heritable hyperlipidemic rabbits. Circulation 1999; 99:2150-2156. (Pubitemid 29196800)
54. Rajamannan NM, Subramaniam M, Springett M, et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 2002; 105:2660-2665. (Pubitemid 34596044)
55. Shiomi M, Yamada S, Ito T. Atheroma stabilizing effects of simvastatin due to depression of macrophages or lipid accumulation in the atheromatous plaques of coronary plaque-prone WHHL rabbits. Atherosclerosis 2005; 178:287-294. (Pubitemid 40193442)
56. Zhou G, Ge S, Liu D, et al. Atorvastatin reduces plaque vulnerability in an atherosclerotic rabbit model by altering the 5-lipoxygenase pathway. Cardiology 2010; 115:221-228.
57. Senokuchi T, Matsumura T, Sakai M, et al. Statins suppress oxidized low density lipoprotein-induced macrophage proliferation by inactivation of the small G protein-p38 MAPK pathway. J Biol Chem 2005; 280:6627-6633. (Pubitemid 40341214)
58. Biwa T, Hakamata H, Sakai M, et al. Induction of murine macrophage growth by oxidized low density lipoprotein is mediated by granulocyte macrophage colony-stimulating factor. J Biol Chem 1998; 273:28305-28313. (Pubitemid 28496131)
59. Hamilton JA, Myers D, Jessup W, et al. Oxidized LDL can induce macrophage survival, DNA synthesis, and enhanced proliferative response to CSF-1 and GM-CSF. Arterioscler Thromb Vasc Biol 1999; 19:98-105. (Pubitemid 29031917)
60. Biwa T, Sakai M, Shichiri M, Horiuchi S. Granulocyte/macrophage colony-stimulating factor plays an essential role in oxidized low density lipoprotein-induced macrophage proliferation. J Atheroscler Thromb 2000; 7:14-20.
61. Matsumura T, Sakai M, Kobori S, et al. Two intracellular signaling pathways for activation of protein kinase C are involved in oxidized low-density lipo-protein-induced macrophage growth. Arterioscler Thromb Vasc Biol 1997; 17:3013-3020. (Pubitemid 28016054)
62. Biwa T, Sakai M, Matsumura T, et al. Sites of action of protein kinase C and phosphatidylinositol 3-kinase are distinct in oxidized low density lipoprotein-induced macrophage proliferation. J Biol Chem 2000; 275:5810-5816. (Pubitemid 30115226)
63. Senokuchi T, Matsumura T, Sakai M, et al. Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase mediate macrophage proliferation induced by oxidized low-density lipoprotein. Atherosclerosis 2004; 176:233-245. (Pubitemid 39369512)
64. Ishii N, Matsumura T, Kinoshita H, et al. Activation of AMP-activated protein kinase suppresses oxidized low-density lipoprotein-induced macrophage proliferation. J Biol Chem 2009; 284:34561-34569.
65. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874. (Pubitemid 36019640)
66. Tabas I. Apoptosis and efferocytosis in mouse models of atherosclerosis. Curr Drug Targets 2007; 8:1288-1296.
67. Isa SA, Ruffino JS, Ahluwalia M, et al. M2 macrophages exhibit higher sensitivity to oxLDL-induced lipotoxicity than other monocyte/macrophage subtypes. Lipids Health Dis 2011; 10:229.
68. Liu J, Thewke DP, Su YR, et al. Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol 2005; 25:174-179. (Pubitemid 40054272)
69. Arai S, Shelton JM, Chen M, et al. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. Cell Metab 2005; 1:201-213. (Pubitemid 43960602)
70. Babaev VR, Chew JD, Ding L, et al. Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis. Cell Metab 2008; 8:492-501.
71. Erbay E, Babaev VR, Mayers JR, et al. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med 2009; 15:1383-1391.
72. Thorp E, Li G, Seimon TA, et al. Reduced apoptosis and plaque necrosis in advanced atherosclerotic lesions of Apoe-/-and Ldlr-/-mice lacking CHOP. Cell Metab 2009; 9:474-481.
73. Lim WS, Timmins JM, Seimon TA, et al. Signal transducer and activator of transcription-1 is critical for apoptosis in macrophages subjected to endo-plasmic reticulum stress in vitro and in advanced atherosclerotic lesions in vivo. Circulation 2008; 117:940-951. (Pubitemid 351272592)
74. Manning-Tobin JJ, Moore KJ, Seimon TA, et al. Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. Arterioscler Thromb Vasc Biol 2009; 29:19-26.
75. Wang BY, Ho HK, Lin PS, et al. Regression of atherosclerosis: role of nitric oxide and apoptosis. Circulation 1999; 99:1236-1241. (Pubitemid 29120097)
76. Gautier EL, Huby T, Witztum JL, et al. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation 2009; 119:1795-1804.
77. Schrijvers DM, De Meyer GR, Herman AG, Martinet W. Phagocytosis in atherosclerosis: molecular mechanisms and implications for plaque progression and stability. Cardiovasc Res 2007; 73:470-480. (Pubitemid 46073944)
78. Gargalovic PS, Gharavi NM, Clark MJ, et al. The unfolded protein response is an important regulator of inflammatory genes in endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26:2490-2496. (Pubitemid 44607470)
79. Myoishi M, Hao H, Minamino T, et al. Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome. Circulation 2007; 116:1226-1233. (Pubitemid 47517533)
80. Ishiyama J, Taguchi R, Akasaka Y, et al. Unsaturated FAs prevent palmitate-induced LOX-1 induction via inhibition of ER stress in macrophages. J Lipid Res 2011; 52:299-307.
81. Todd DJ, Lee AH, Glimcher LH. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol 2008; 8:663-674.
82. Colles SM, Maxson JM, Carlson SG, Chisolm GM. Oxidized LDL-induced injury and apoptosis in atherosclerosis. Potential roles for oxysterols. Trends Cardiovasc Med 2001; 11:131-138. (Pubitemid 33070336)
83. Lee K, Tirasophon W, Shen X, et al. IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes Dev 2002; 16: 452-466. (Pubitemid 34165102)
84. Yoshida H, Matsui T, Yamamoto A, et al. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 2001; 107:881-891. (Pubitemid 34084979)
85. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8:519-529. (Pubitemid 46985379)
86. Szegezdi E, Logue SE, Gorman AM, Samali A. Mediators of endo-plasmic reticulum stress-induced apoptosis. EMBO Rep 2006; 7:880-885. (Pubitemid 44523966)
87. Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 2004; 11:381-389. (Pubitemid 38489416)
88. Timmins JM, Ozcan L, Seimon TA, et al. Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways. J Clin Invest 2009; 119:2925-2941.
89. Seimon TA, Obstfeld A, Moore KJ, et al. Combinatorial pattern recognition receptor signaling alters the balance of life and death in macrophages. Proc Natl Acad Sci USA 2006; 103:19794-19799. (Pubitemid 46037510)
90. Hallett JM, Leitch AE, Riley NA, et al. Novel pharmacological strategies for driving inflammatory cell apoptosis and enhancing the resolution of inflammation. Trends Pharmacol Sci 2008; 29:250-257.
91. Perretti M, D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 2009; 9:62-70.
92. Laufer EM, Winkens MH, Narula J, Hofstra L. Molecular imaging of macro-phage cell death for the assessment of plaque vulnerability. Arterioscler Thromb Vasc Biol 2009; 29:1031-1038.
93. Wickline SA, Neubauer AM, Winter PM, et al. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging 2007; 25:667-680. (Pubitemid 46516717)